Stockreport

Immunovant stock falls 8% amid Graves' disease program update Sep. 09, 2024 5:18 PM ET By: Val Brickates Kennedy , SA News Editor [Seeking Alpha]

Immunovant, Inc.  (IMVT) 
PDF of Graves' disease, adding the FDA has cleared it to begin a pivotal trial of its drug candidate IMVT-1402 for the same disease. The biotech company said the Phase 2 [Read more]